Notifications
Back

AAVATAR THERAPEUTICS


ABOUT


AAVATAR Therapeutics is dedicated to enhancing the quality of life for patients with rare and intractable diseases by revolutionizing medicine through its AAV gene therapy platform.


Leveraging our expertise in AAV capsid and promoter engineering, we develop efficacious and economically viable therapeutics. Our comprehensive services encompass customized therapeutic design, engineering, and production.


AAVATAR Therapeutics is dedicated to enhancing the quality of life for patients with rare and intractable diseases by revolutionizing medicine through its AAV gene therapy platform.


Leveraging our expertise in AAV capsid and promoter engineering, we develop efficacious and economically viable therapeutics. Our comprehensive services encompass customized therapeutic design, engineering, and production.


HISTORY

2025


06Certified as an Excellent Company for Employee Invention Compensation
05Selected for the Next Challenge Global Collaboration Program with Astellas
04

Chosen as a joint research partner for the Ministry of Health and Welfare’s Genome Editing-Based Therapeutics Development Program


2024


12
Innobiz company certification completed
11
Adeno-associated virus mutant patent application
10
Patent registration for high-yield, high-quality recombinant adeno-associated virus production method
08
Selection of Global Industrial Technology Cooperation Center project (joint research institute)
08
Selection of 2024 Seoul-type R&D biomedical technology commercialization support project
07
Patent application for BEST1 gene editing method using CRISPR/Cas system
05
Selection of baby unicorn fostering project
05
Selection of scale-up tips project


2023


10
Series A 5 billion won investment attraction completed
(TS Investment, Shinhan Capital, Smilegate Investment, Wonik Investment Partners)
4
Selected as one of 100 startups in materials, parts, and equipment


2022


12
Completed application for provisional specification of Korean patent for recombinant AAV manufacturing method
09
Expansion of business location
(Addition of 1021 and 1022, B-dong 2, Hanam Hyundai Knowledge Industry Center Hangang Misa)
08
A total of 8 government projects and support projects selected
(Cumulative government and local government support project cost of approximately 6.5 billion won),
Recruitment of first research institute director and strategic planning headquarters director
07
Selection of Gyeonggi-do type smart factory construction support project
07
Ministry of Health and Welfare regenerative medicine clinical research infrastructure establishment project cell gene therapy

Project selected for development of virus materials and production technology for production
(5 years of research and development period, total project cost of 5.4 billion won)


2021


12
Selected for TIPS Startup Commercialization Project (Public-Private Joint Entrepreneur Discovery and Incubation Project),
Selected for Seoul Biohub Entry Permit Company (BT-IT Convergence Center) and Completed Installation of Seoul Branch
11
Venture business certification completed, corporate research institute LMO & Biosafety Level 2 approval completed
10
Konkuk University School of Medicine and Rare and Incurable Disease Pipeline MOU signed for joint research
08
Business location Hanam Hyundai Knowledge Industry Center Moved into 1023 (headquarters), 1014 (laboratory) of B-dong 2, Hangang Misa(including relocation of corporate research institute)
07
2 papers published, technology transfer agreement with Kyungpook National University, Selected as a project for TIPS R&D Startup Growth Technology Development Project
05
Innopolis Partners (Ltd.) Attracts seed investment (headquarters), Establishes corporate research institute


2020


09
Establishment of Aavatar Therapeutics Inc.


OUR MISSION

MISSON 01

Core Compentency


We employ world-class technologies in gene therapy production and analysis, leading medical innovation through a premier R&D organization and the nation's top hospital network. Our efforts are driven by the dedication of our long-standing key personnel, all aimed at enhancing human quality of life.



MISSON 02

Core Value


We grow together based on generosity and trust in ourselves and our colleagues, and we inspire through excellence. We act with honesty and courage, pursue genuine connections with our customers, and foster an entrepreneurial spirit. We also achieve continuous improvement through frugality and innovation.



MISSON 03

Responsibility


We contribute to solving human health problems by providing innovative treatments and platforms to patients suffering from serious untreated diseases and to treatment development companies.


TEAM

Cho Seung Hee


CEO & CMC Headquarters Manager



• Ph.D. in Biochemistry & Biophysics, University of Minnesota, Twin-cities, USA
• Research scholar, Department of Chemistry, University of Washington, Seattle, USA
• Bachelor's degree (Life Science/Computer Engineering) from Handong University

• Former Process Team Leader, CMC, Newracle Genetics

Song Dong Woo


Chief Technology Officer, Managing Director & Head of R&D Headquarters



• General Manager of Research Institute Work

• Progress of Eye Pipeline

• General Manager of Machine Learning-based Modeling

• Ph.D. in Molecular Biology, Gwangju Institute of Science and Technology

• Former Head of Toolgen Research Institute

Park Sang Ho


Chief Strategy Officer, Managing Director & Head of Strategy Planning Headquarters



• Seoul National University Bachelor's, Master's, Doctorate (Virology)

• Joint research response

• Project/BD responsibility

• Preclinical customer acquisition

• IP portfolio strategy collection

• Domestic and international trend survey external cooperation

• Establishment of major pipeline development strategy

• Former Head of R&D Strategy Office, Toolgen Inc.

Lee Ho Hyun


General Manager, Platform and Therapeutics Research Institute



• Bachelor's, Master's, and Doctorate degrees (Chemical and Bioengineering) from Sogang    

   University

• Former R&D Manager at Daewoong Pharmaceutical

• Former R&D Manager at Toolgen Co., Ltd.

Hong Yoon Taek


Head of Management Support Division



• Bachelor's degree (Life Sciences) from Korea University (Anam)

• Former R&D manager at Noeul Co., Ltd.

• Project and external cooperation manager

• Personnel, accounting, and administrative management


Scientific Advisory Board (SAB)

and Research Collaborators


Professor Cho Seong Rae

(M.D.-Ph.D.)


  • Yonsei University College of Medicine, Ph.D. (Rehabilitation Medicine)
  • Yonsei University Sinchon Severance Hospital, Department of Rehabilitation Medicine
  • Krabbe disease (LSD) collaboration


Professor Lee Sang Yeon

(M.D.-Ph.D.)


  • Seoul National University College of Medicine, Ph.D. (Otorhinolaryngology)
  • Seoul National University Hospital, Otorhinolaryngology
  • Collaboration on Gene Therapy for Congenital Deafness


Professor Cho Seong-yoon

(M.D.-Ph.D.)


  • Graduated from Ewha Womans University College of Medicine
  • Ph.D. from Sungkyunkwan University Graduate School of Medicine
  • Samsung Seoul Hospital Pediatric Endocrinology, Genetics, and Metabolism
  • Collaboration on Gene Therapy for Pediatric LSD Disease


Lawyer Lee Yeo Won


  • Current) Partner Attorney at Law Firm Hwahyun
  • Completed the 40th Judicial Research and Training Institute

  • Graduated from Seoul National University Law School

  • Attorney at Law Firm Pacific Securities and Finance Team

  • LG Life Sciences Legal Team

  • LG Chem Domestic Legal Team
  • Partner Attorney at Law Firm Jeonghyang and Law Firm Taesung

                                                   

Lawyer Choi Mi Yeon


  • Current) Representative Attorney of Panacea Law Firm

  • Passed the 55th Bar Examination

  • Completed the 45th Judicial Research and Training Institute

  • Graduated from Korea University Law School

  • Master's Program in Administrative Law, Korea University Graduate School

  • Expert Committee Member, Regulatory Reform Legal Affairs Office, Ministry of Health and Welfare

  • In-house Attorney at Pharmaceutical Company


Attorney Noh Young Joo


  • Current) Patent Attorney at Iplay Patent Law Firm
  • Bachelor's degree in Biological Education, Seoul National University

  • Master's degree in Pharmaceutical Industry, Sungkyunkwan University

VISION


01
AAV Therapy Platform & Production Tech


Our goal is to become Asia’s leading gene therapy company by developing innovative platforms, advancing production technologies, and facilitating technology transfers that enrich the ecosystem.


02
Establishing brand value


We are establishing our status as the No. 1 brand in the gene therapy field and as a leading job-creating company in Korea, driving market leadership through continuous innovation and advanced technologies.


03
Building a global network


By establishing two or more overseas branches, we will expand our global network and strengthen our competitiveness in the international market, thereby growing into a global bio company.

CI

Main Logo


The AAVATAR Therapeutics logo is a helical DNA symbol that represents the core values of AAVATAR Therapeutics, which provides good treatments to all those in need using genetic modification technology.


The blue and geometric logotype, which symbolize trust and professionalism, symbolize the brand identity of AAVATAR Therapeutics, a platform that solves human health problems.

Color System


Exclusive colors are an important element that forms the brand identity of AAVATAR Therapeutics. Depending on the characteristics of the application medium, both the 5 primary colors and spot colors can be used.


When printing, please maintain PANTONE colors and CMYK colors.

CI



Main Logo


The AAVATAR Therapeutics logo is a helical DNA symbol that represents the core values of AAVATAR Therapeutics, which provides good treatments to all those in need using genetic modification technology.


The blue and geometric logotype, which symbolize trust and professionalism, symbolize the brand identity of AAVATAR Therapeutics, a platform that solves human health problems.

Color System


Exclusive colors are an important element that forms the brand identity of AAVATAR Therapeutics. Depending on the characteristics of the application medium, both the 5 primary colors and spot colors can be used.


When printing, please maintain PANTONE colors and CMYK colors.

Innovation in gene therapy, changing the lives of patients with rare and incurable diseases.


We are with you through the entire process of rare disease treatment, from the development of AAV platform technology to the production of customized treatments.



MON — FRI (8 AM ~ 5 PM)

TEL  |  070-4229-0321

EMAIL  |  information@aavatartps.com



COMPANY  |  AAVATAR Therapeutics

CEO  |  Seunghee Cho

BUSINESS NUMBER  |  235-81-02296


HQ

Unit 1023, Building B, 540 Misa-daero,

Hanam-si, Gyeonggi-do, Republic of Korea


BioHub

Room 203, R&D Center, Seoul Bio Hub, 117-3,

Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea


Copyright ⓒ 2025 AAVATAR Therapeutics All rights reserved.

Innovation in gene therapy, changing the lives of patients with rare and incurable diseases.



We are with you through the entire process of rare disease treatment, from the development of AAV platform technology to the production of customized treatments.

MON — FRI (8 AM ~ 5 PM)

TEL  |  070-4229-0321

EMAIL  |  information@aavatartps.com

COMPANY  |  AAVATAR Therapeutics    CEO  |  Seunghee Cho      BUSINESS NUMBER  |  235-81-02296

HQ  |  Unit 1023, Building B, 540 Misa-daero, Hanam-si, Gyeonggi-do, Republic of Korea

BioHub  |  Room 203, R&D Center, Seoul Bio Hub, 117-3, Hoegi-ro, Dongdaemun-gu, Seoul, Republic of Korea


Copyright ⓒ 2025 AAVATAR Therapeutics All rights reserved. |  SITE BY. DOTCLE